Evidence map›Paper›PMID 38192991›Full record

ArticleTranslational cancer research2023

Predictors of central line-associated bloodstream infections in cancer patients undergoing chemotherapy through implanted venous access ports: a retrospective, observational study.

Hao Chen, Takamasa Yamane, Terunobu Haruyama, Masashi Ishihara, Hiroki Kazahari, Takahiko Sakamoto, Shigeru Tanzawa, Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Lumbar methicillin-resistantWorld journal of clinical cases · 2025
    Article
  3. Article
  4. Thrombosis and infections associated with PICC in onco-hematological patients, what is their relevance?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Hao Chen *Department of Oncology, Teikyo University Hospital, Tokyo, Japan.
Takamasa Yamane *Department of Oncology, Teikyo University Hospital, Tokyo, Japan.
Terunobu HaruyamaDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Masashi IshiharaDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Hiroki KazahariDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Takahiko SakamotoDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Shigeru TanzawaDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Takeshi HondaDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Yasuko IchikawaDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Kiyotaka WatanabeDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Nobuhiko SekiDepartment of Oncology, Teikyo University Hospital, Tokyo, Japan.
Teikyo University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Central venous catheters (CVCs) are sometimes superior to peripheral vascular access for chemotherapy. Central line-associated bloodstream infections (CLABSIs) are an important complication of CVCs in chemotherapy. Methods: A retrospective, observational study was conducted to investigate patients with implanted venous access ports (PORTs) from July 2010 to June 2021 in a teaching hospital. General conditions of the PORTs, backgrounds, and characteristics of patients were compared between CLABSI cases and uninfected cases to identify predictors of CLABSI. Results: A total of 566 patients with PORTs who underwent chemotherapy were enrolled in this study, with CLABSI identified in 41 patients, for a total of 436,597 catheter-days. The median duration of PORT use was 26 Conclusions: PORT implantation should be avoided in patients who had antibiotic treatment episodes within 1 week, especially for those with low serum TP levels.

Indexed as

central line-associated bloodstream infection (CLABSI)Central venous catheters (CVCs)chemotherapy

Identifiers

PMID38192991
PMCPMC10774051
OpenAlexW4390372401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.